Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5900879 | 0.98 | CASP1 (0.50) | CASP1FLT1FLT4KDRKMT2A | |
| SCHEMBL3211886 | 0.85 | CASP1 (0.55) | CASP1FLT1FLT4KDRKMT2A | |
| SCHEMBL30818930 | 0.85 | CASP1 (0.55) | CASP1FLT1FLT4KDRKMT2A | |
| SCHEMBL508503 | 0.83 | TSHR (0.57) | CASP1FLT1FLT4KDRAVPR2 | |
| SCHEMBL6628485 | 0.83 | FLT1 (0.52) | CASP1FLT1FLT4KDRAVPR2 | |
| SCHEMBL3379668 | 0.81 | KMT2A (0.49) | CASP1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL27232968 | 0.81 | FLT1 (0.44) | CASP1FLT1FLT4KDRAVPR2 | |
| SCHEMBL3362814 | 0.81 | FLT1 (0.51) | FLT1FLT4KDRAVPR2GPR27 | |
| SCHEMBL5045602 | 0.79 | XDH (0.49) | CASP1MKNK1MKNK2PARP15PARP10 | |
| SCHEMBL24022839 | 0.78 | CASP1 (0.44) | CASP1KDRPARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795177-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-23 | — | — | CN | claimed |
| CN-107683283-A | Bace1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-09 | — | — | CN | claimed |
| CN-106795177-A | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | claimed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | claimed |
| CN-106795177-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-107683283-A | Bace1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-106795177-A | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | ABBOTT GMBH & CO. KG (DE) | 2006-05-25 | — | — | US | disclosed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | BOHM HANS-JOACHIM (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6455671-B1 | COMPOUND FOR USE IN THE TREATMENT OF THROMBOSIS | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, F2, TFPI2 | CASP1 473/4885FLT1 226/4885FLT4 493/4885 |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, SERPINC1, F2 | CASP1 203/4885FLT1 165/4885FLT4 570/4885 |
| US-20080255240-A1 | Sulfonamide Derivatives | FABP4, SQOR, CS | CASP1 3504/4885FLT1 4429/4885FLT4 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.